CORDIS - Forschungsergebnisse der EU
CORDIS

Photoswitchable amphiphilic lipids: a photopharmacology strategy to combat drug-resistant bacterial infections.

Projektbeschreibung

Neuartige lichtaktivierte antimikrobielle Mittel

Antimikrobielle Resistenz entwickelt sich immer mehr zu einem erheblichen medizinischen Problem – viele Krankheitserreger, die mit Antibiotika bekämpft werden konnten, sind plötzlich resistent. Daher sind unbedingt neue Arzneimittel erforderlich. Das EU-finanzierte Projekt PhotoLiB hat antimikrobieller Resistenz den Kampf angesagt und entwickelt Arzneimittel auf Lipidbasis, die durch Licht aktiviert werden können. Die Nutzung von Licht zur Veränderung der chemischen Eigenschaften von Arzneimitteln wird Photopharmakologie genannt – ein vielversprechender Ansatz, da Licht ungiftig ist und mit hoher Präzision an spezifische Zielorte geleitet werden kann. Die Arzneimittel von PhotoLiB werden Bakterienmembranen durchdringen und zerstören können und daher eine sichere Alternative zu bisherigen antimikrobiellen Mitteln sein.

Ziel

Antimicrobials have saved millions of lives since they were first discovered. Unfortunately, today the world is facing up a global antibiotic resistance health emergency. In fact, bacterial infections which have been susceptible to standard antibiotic regimes for decades are now becoming resistant to all major antimicrobial treatments, making their efficacy undermined. Within this context, this proposal aims to develop a new and original strategy to combat antimicrobial resistance. Photopharmacology is a novel and emerging medical approach which exploits light to modulate the activity of drugs. The energy of light, which is not toxic to humans and easily delivered with high precision, can be used to change, at will, the conformation and chemical properties of drugs, making them more selective and efficient. This project wants to apply the photopharmacology concept to amphiphilic lipid drugs, namely those molecules bearing a polar head and a lipid tail acting as antimicrobials through disruption of bacterial membranes. Since, unlike other proteins and enzymes, membranes cannot mutate, they are ideal targets to combat antimicrobial resistance. New Photoswitchable Amphiphilic Lipis (PALs), able to intercalate the bacterial membranes, will be developed and synthesised by inserting a photoactivable probe into a amphiphilic lipid. Upon light irradiation, these PALs will change conformation leading, selectively, to membrane damage and consequent cell death. A set of 20 PALs will be synthesised and the compounds will be evaluated against a panel of bacteria, alone or in synergistic combination with other antibiotics. Preliminary in-vivo studies on Galleria models will be carried out as well as NMR-metabolomic studies to elucidate the key interactions of PALs with living systems and the response of bacteria to the action of these new drugs. The data generated through this project will create new means and opportunities in the fight against bacterial resistance.

Koordinator

UNIVERSITY COLLEGE LONDON
Netto-EU-Beitrag
€ 151 686,91
Adresse
GOWER STREET
WC1E 6BT London
Vereinigtes Königreich

Auf der Karte ansehen

Region
London Inner London — West Camden and City of London
Aktivitätstyp
Higher or Secondary Education Establishments
Links
Gesamtkosten
€ 151 686,91

Beteiligte (1)